A Post-Market Clinical Investigation on Mepilex Border Post-Op

NCT ID: NCT04994145

Last Updated: 2021-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

560 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-01

Study Completion Date

2021-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a retrospective, observational (non-interventional), single-arm, single-centre, post-market clinical investigation designed to verify clinical performance and safety of Mepilex Border Post-Op when used according to clinical practice for post-operative wounds in a large and broad population.

The clinical investigation will consist of a retrospective medical record review, which will be completed with data from up to 450 female and male adult subjects who were treated with Mepilex Border Post-Op following elective hip or knee replacement at one clinic in Belgium between January 2016 and February 2021.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mepilex Border Post-Op is a CE-marked class IIa medical device developed, manufactured and marketed by Mölnlycke Health Care AB. This is a retrospective, observational (non-interventional), single-arm, single-centre, post-market clinical investigation designed to verify clinical performance and safety of Mepilex Border Post-Op when used according to clinical practice for post-operative wounds in a large and broad population. The overall objective of this investigation is to confirm the clinical performance of Mepilex Border Post-Op for post-operative wounds when used according to clinical practice, by assessing dressing wear time from day of surgery to end of dressing use.

The clinical investigation will consist of a retrospective medical record review, which will be completed with data from up to 450 female and male adult subjects who were treated with Mepilex Border Post-Op following elective hip or knee replacement at one clinic in Belgium between January 2016 and February 2021. The data collected for each subject will include those generated in relation to the surgery itself as well as the pre- and post-surgery phases. There is no available data for subjects treated with an alternative to Mepilex Border Post-Op to use as a control group, however, the pre-surgery data will serve as control for some endpoints.

The treatment the subjects received at the clinic included pre-surgery visits, the surgery itself, a short in-patient stay following surgery, and post-surgery follow-up visits at approximately 14 days, 1.5 months, 3 months, 6 months, and 1 year. In addition, the subjects used the commercially available mobile health application moveUP Therapy to support their rehabilitation. The subjects' rehabilitation was tracked and aided with moveUP Therapy as it allows (1) subjects to answer a number of questionnaires; (2) subjects to communicate with their surgeon and physical therapist via a chat function in the app; and (3) subject-specific log entries by the surgeon and physical therapist. The data to be used in this retrospective investigation will be extracted exclusively from moveUP Therapy.

Eligible subjects/medical records will be identified by site personnel through screening moveUP Therapy. Only data from subjects who have consented to the use of their data related to the surgery in an anonymous way for medical research and scientific publications will be extracted.

The investigational device, Mepilex Border Post-Op, was applied as part of the surgery. In the rare event that a dressing change would be required, the subjects were provided with spare dressings and instructions for how to do the change by the treating surgeon or clinic nurse. These instructions included only changing the dressing once at least three corners of the dressing were stained with blood, and to consult the treating surgeon or clinic nurse by sending a moveUP Therapy chat message with a picture of the dressing requesting advice on whether to change or not.

Dressing wear time will be derived from up to three sources:

1. how frequently the subjects have answered the question "Is the dressing dry?" with "Yes, it was changed today";
2. review of potential Health Care Professional log entries for evidence of dressing change(s); and
3. review of potential moveUP Therapy chat messages, including photographs, for evidence of dressing change(s).

Total number of dressings per subject will be derived from the same information as dressing wear time.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Surgical Wound

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Medical Device Mepilex Border Post-Op Knee replacement Hip replacement Surgical wound Dressing Wear time

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Underwent elective knee or hip surgery between January 2016 and February 2021 at the Medisch Centrum Latem, Belgium.
2. Post-operative wound treated with Mepilex Border Post-Op
3. Documented consent in moveUP Therapy
4. Documented consent at Medisch Centrum Latem during pre-op consultation

Exclusion Criteria

1\. Subject missing all answers to the moveUP Therapy question "Is the dressing dry?"
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Molnlycke Health Care AB

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medisch Centrum Latem

Sint-Martens-Latem, , Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Camilla Fardell, Ph.D.

Role: CONTACT

Phone: +46317223402

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Wouter Van Lysebettens

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PD-612416

Identifier Type: -

Identifier Source: org_study_id